GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351 · Terminated

Last updated 2026-05-28

This clinical trial is testing whether a medication called a GLP-1 receptor agonist can reduce kidney-related protein loss in adults with type 2 diabetes.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 15 people

Who can join Ages 18–85 · all sexes

Timeline Started 2017-01 · est. completion 2019-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03029351 ↗

Description as written by the study sponsor.

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Treatments tested

Exenatide Extended Release for Inj Susp 2 MG also known as Bydureon Drug

Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
Placebo Drug

placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria

Main thing measured	Change From Baseline in Urinary Albuminuria Levels
Sponsor	University at Buffalo
Conditions studied	Type2 Diabetes, Kidney Diseases
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03029351 ↗